Homrich & Berg’s AstraZeneca AZN Stock Holding History

Homrich & Berg’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$357K	Buy	2,972 +510	+21%	+$59.4K	0.01%	338
2021 Q2	$295K	Buy	2,462 +37	+2%	+$4.06K	0.01%	371
2021 Q1	$241K	Sell	2,425 -90	-4%	-$9.05K	0.01%	369
2020 Q4	$251K	Hold	2,515	–	–	0.01%	351
2020 Q3	$276K	Sell	2,515 -521	-17%	-$57.9K	0.01%	274
2020 Q2	$321K	Buy	3,036 +449	+17%	+$46.4K	0.01%	247
2020 Q1	$231K	Buy	2,587 +40	+2%	+$3.77K	0.01%	266
2019 Q4	$254K	Buy	+2,547	New	+$240K	0.01%	313
2014 Q2	–	Sell	-3,723	Closed	-$242K	–	203
2014 Q1	$242K	Sell	3,723 -184	-5%	-$11.9K	0.03%	182
2013 Q4	$232K	Buy	+3,907	New	+$212K	0.03%	179

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Homrich & Berg's AZN Position: Q3 2021 in Review

Homrich & Berg increased its AstraZeneca (AZN) stake by 21% in Q3 2021, buying an estimated $59.4K and bringing the position to 2,972 shares worth $357K. The position accounts for 0.01% of the portfolio, ranked #338.

Homrich & Berg first reported a position in AZN in Q4 2013 and has held it in 10 quarters since. 905 funds tracked by Wall St. Rank hold AZN as of Q3 2021.

Homrich & Berg held 2,972 shares of AstraZeneca worth $357K as of Q3 2021.
Homrich & Berg bought 510 AstraZeneca shares in Q3 2021, an estimated $59.4K.
AstraZeneca made up 0.01% of Homrich & Berg's portfolio in Q3 2021, its #338 holding.
Homrich & Berg first reported a position in AstraZeneca in Q4 2013 and has held it in 10 quarters since.
905 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2021.

Based on Homrich & Berg's 13F filing for Q3 2021, filed 8 Dec 2021.